Reprogramming based gene therapy for inherited red blood cell disorders.
作者信息
Xu Xiuling, Qu Jing, Suzuki Keiichiro, Li Mo, Zhang Weizhou, Liu Guang-Hui, Izpisua Belmonte Juan Carlos
机构信息
National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
出版信息
Cell Res. 2012 Jun;22(6):941-4. doi: 10.1038/cr.2012.54. Epub 2012 Apr 3.
Abstract
摘要
相似文献
1
Reprogramming based gene therapy for inherited red blood cell disorders.基于重编程的遗传性红细胞疾病基因治疗
Cell Res. 2012 Jun;22(6):941-4. doi: 10.1038/cr.2012.54. Epub 2012 Apr 3.
2
Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier.利用诱导多能干细胞（iPSC）治疗β地中海贫血和镰状细胞病的基因与细胞疗法：新的前沿领域。
Adv Exp Med Biol. 2017;1013:219-240. doi: 10.1007/978-1-4939-7299-9_9.
3
A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.一种通用方法可纠正人类干细胞中的各种 HBB 基因突变，用于β-地中海贫血和镰状细胞病的基因治疗。
Stem Cells Transl Med. 2018 Jan;7(1):87-97. doi: 10.1002/sctm.17-0066. Epub 2017 Nov 21.
4
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.通过慢病毒转导β(A(T87Q))-珠蛋白基因对β-血红蛋白病进行基因治疗
Hum Gene Ther. 2016 Feb;27(2):148-65. doi: 10.1089/hum.2016.007.
5
Reprogramming of bone marrow derived mesenchymal stromal cells to human induced pluripotent stem cells from pediatric patients with hematological diseases using a commercial mRNA kit.使用商用mRNA试剂盒将血液系统疾病儿科患者的骨髓来源间充质基质细胞重编程为人类诱导多能干细胞。
Blood Cells Mol Dis. 2019 May;76:32-39. doi: 10.1016/j.bcmd.2019.01.003. Epub 2019 Jan 24.
6
In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases.利用工程化锌指核酸酶在人诱导多能干细胞中对镰状细胞贫血突变进行原位基因校正。
Stem Cells. 2011 Nov;29(11):1717-26. doi: 10.1002/stem.718.
7
Gene Therapy for β-Hemoglobinopathies.β-血红蛋白病的基因治疗
Mol Ther. 2017 May 3;25(5):1142-1154. doi: 10.1016/j.ymthe.2017.03.024. Epub 2017 Apr 1.
8
Gene replacement therapy for sickle cell disease and other blood disorders.镰状细胞病和其他血液疾病的基因替代疗法。
Hematology Am Soc Hematol Educ Program. 2008:193-6. doi: 10.1182/asheducation-2008.1.193.
9
Generation and characterization of induced pluripotent stem cell line (IGIBi001-A) from a sickle cell anemia patient with homozygous β-globin mutation.来自一名患有纯合β-珠蛋白突变的镰状细胞贫血患者的诱导多能干细胞系（IGIBi001-A）的产生与鉴定
Stem Cell Res. 2019 Aug;39:101484. doi: 10.1016/j.scr.2019.101484. Epub 2019 Jun 14.
10
Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.从一名患有镰状细胞病的成年患者中诱导的人多能干细胞中对一个点突变的基因进行位点特异性修正。
Blood. 2011 Oct 27;118(17):4599-608. doi: 10.1182/blood-2011-02-335554. Epub 2011 Aug 31.
引用本文的文献
1
Artificial blood for therapeutic and laboratory usage: Where do we stand?用于治疗和实验室用途的人造血液：我们目前的进展如何？
Biomicrofluidics. 2024 Sep 25;18(5):051505. doi: 10.1063/5.0186931. eCollection 2024 Sep.
2
Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing.用 NK 细胞缺陷治疗原发性免疫缺陷：从干细胞治疗到基因编辑。
Stem Cell Res Ther. 2020 Oct 27;11(1):453. doi: 10.1186/s13287-020-01964-5.
3
Concurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC.重编程与基因校正的同步进展以克服突变型ALK2-iPSC的治疗局限性。
Exp Mol Med. 2016 Jun 3;48(6):e237. doi: 10.1038/emm.2016.43.
4
Eliminate mitochondrial diseases by gene editing in germ-line cells and embryos.通过对生殖细胞和胚胎进行基因编辑来消除线粒体疾病。
Protein Cell. 2015 Jul;6(7):472-5. doi: 10.1007/s13238-015-0177-x.
5
The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders.细胞穿透肽在蛋白质细胞内递送给治疗红细胞相关疾病中的潜在作用。
Pharmaceuticals (Basel). 2013 Jan 7;6(1):32-53. doi: 10.3390/ph6010032.
6
Pluripotent stem cells and gene therapy.多能干细胞与基因治疗。
Transl Res. 2013 Apr;161(4):284-92. doi: 10.1016/j.trsl.2013.01.001. Epub 2013 Jan 23.
本文引用的文献
1
Overcoming reprogramming resistance of Fanconi anemia cells.克服范可尼贫血细胞的重编程抵抗。
Blood. 2012 Jun 7;119(23):5449-57. doi: 10.1182/blood-2012-02-408674. Epub 2012 Feb 27.
2
Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice.β-地中海贫血症患者特异性 iPS 细胞的基因矫正及其在改善辐照 SCID 小鼠血红蛋白生成中的应用。
Cell Res. 2012 Apr;22(4):637-48. doi: 10.1038/cr.2012.23. Epub 2012 Feb 7.
3
In vitro generation of red blood cells for transfusion: a model for regenerative medicine.用于输血的红细胞的体外生成：再生医学模型。
Regen Med. 2012 Jan;7(1):1-2. doi: 10.2217/rme.11.108.
4
Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs.在无整合的患者诱导多能干细胞中通过同源重组有效校正导致血红蛋白病的突变。
Cell Res. 2011 Dec;21(12):1740-4. doi: 10.1038/cr.2011.186. Epub 2011 Nov 22.
5
In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases.利用工程化锌指核酸酶在人诱导多能干细胞中对镰状细胞贫血突变进行原位基因校正。
Stem Cells. 2011 Nov;29(11):1717-26. doi: 10.1002/stem.718.
6
Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.从一名患有镰状细胞病的成年患者中诱导的人多能干细胞中对一个点突变的基因进行位点特异性修正。
Blood. 2011 Oct 27;118(17):4599-608. doi: 10.1182/blood-2011-02-335554. Epub 2011 Aug 31.
7
Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs.靶向纠正患者特异性 iPSC 中与层粘连蛋白病相关的 LMNA 突变。
Cell Stem Cell. 2011 Jun 3;8(6):688-94. doi: 10.1016/j.stem.2011.04.019. Epub 2011 May 19.
8
[Hemolytic anemia in adults: Main causes and diagnostic procedure].[成人溶血性贫血：主要病因及诊断方法]
Presse Med. 2011 May;40(5):470-85. doi: 10.1016/j.lpm.2010.11.013. Epub 2011 Feb 4.
9
Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells.基因组安全港可允许地中海贫血诱导多能干细胞中高β-珠蛋白转基因的表达。
Nat Biotechnol. 2011 Jan;29(1):73-8. doi: 10.1038/nbt.1717. Epub 2010 Dec 12.
10
Direct conversion of human fibroblasts to multilineage blood progenitors.人类成纤维细胞向多谱系造血祖细胞的直接转化。
Nature. 2010 Nov 25;468(7323):521-6. doi: 10.1038/nature09591. Epub 2010 Nov 7.
Zotero 插件